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ABSTRACT
Background: Population means of conventional cardiovascular biomarkers are known to differ
between ethnic groups. In this study we performed detailed comparisons in the temporal pattern of
these biomarkers between Caucasian and Chinese diabetic patients with acute coronary syn-
drome (ACS).
Methods: We studied differences in temporal changes of established cardiovascular biomarkers,
including high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, cardiac
Troponin T (TnT), NT-proBNP and C-reactive protein (CRP), in 48 Chinese and 48 clinically matched
Caucasian patients with type 2 diabetes mellitus who were admitted for ACS. Blood samples were col-
lected at regular time intervals during 30days to 1 year after the index ACS.
Results: In the >30day post ACS period, mean serum levels of LDL (2.16 vs. 1.47mmol/L; p-value
<0.001), total cholesterol (4.08 vs. 3.11mmol/L; p-value <0.001), TnT (11.0 vs. 7.76 ng/L; p-value 0.010)
and CRP (2.0 vs. 0.78mg/L; p-value <0.001) were systematically higher in Caucasian than in Chinese
patients. HDL and NT-proBNP levels were similar.
Conclusions: Our study showed clinically relevant differences in levels of established cardiovascular
biomarkers between Caucasian and Chinese post ACS patients. Further cross-ethnic studies are war-
ranted to determine secondary prevention treatment biomarker targets in specific populations.
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Introduction
For decades coronary artery disease (CAD) has been the lead-
ing cause of mortality and morbidity worldwide (Shepard
et al. 2015, Roth et al. 2017). Global analyses have demon-
strated a favourable trend in economically developed
(Western) countries with declining (age-standardized) CAD
mortality rates over the past decennia, whereas its incidence
is increasing in non-Western regions ( Roth et al. 2015,
Joseph et al. 2017, Roth et al. 2017). Various factors are
attributable for this epidemiological shift, but fact is that
CAD has become a major burden to non-Western societies
(Reddy, 2004).
Recognition of CAD onset in the asymptomatic phase is
the cornerstone of successful primary prevention. Also, in
patients with established disease, the success of secondary
prevention depends on early recognition of individuals with
high risk of cardiovascular (CV) events. Blood biomarkers,
reflecting underlying pathophysiological processes, can be
instrumental in this respect (Wang et al. 2017). For example,
inflammatory markers, such as C-reactive protein (CRP) and
interleukin-18, have been extensively studied and shown to
be a valuable predictor for adverse outcomes in patients
with CAD (He et al. 2010, Cheng et al. 2015). Thus far, most
CV biomarkers have been merely validated in Caucasians,
and little is known about their generalizability to other eth-
nic groups. Furthermore, existing inter-ethnic CV biomarker
studies have focussed on general populations (Gijsberts et al.
2015), and biomarker data in CAD populations from different
ethnic groups are scarce. Finally, inter-ethnic biomarker
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studies are typically characterized by cross-sectional designs,
with single measurements at a certain baseline moment.
Hence, the observed results might easily be affected by acci-
dental factors. Insight into longitudinal biomarker patterns
by means of repeated blood sampling may nullify these ran-
dom variations, and thus reveal true differences in biomarker
levels between populations.
The need for biomarker validation in order to optimize
secondary prevention strategies is especially warranted in
Asia, where CAD now is an upcoming epidemic (Reddy,
2004). Concerns especially exist in the (rural) Chinese popu-
lation, where an increasing number of patients with coron-
ary heart disease is leading to rapidly increasing mortality
rates (Li and Ge 2015). Similar to this worrisome trend are
the rising numbers in prevalence of diabetes mellitus type
2 (DM2), which has become a serious health concern, lead-
ing to the world’s largest epidemic in China (Chan et al.
2009, Wang et al. 2017). The joint effect of established cor-
onary heart disease and prevalent diabetes markedly
increase the risk of coronary mortality (Hu et al. 2005).
Biomarkers should especially be further investigated in
these high-risk groups, since they are particularly prone to
recurrent events and might benefit most from secondary
prevention strategies. Nevertheless, biomarker studies in
Asian populations have been mainly focussed on South
Asians (Gijsberts et al. 2015). But, within Asia, there is broad
geographical variation in patient risk profiles, which makes
it unlikely that findings from South Asians can easily be
extrapolated to Chinese individuals. In fact, far less bio-
markers have been investigated in Chinese cohorts, residing
in their country of origin.
Against this background, we evaluated differences in lev-
els of serum high-density lipoprotein (HDL), low-density
lipoprotein (LDL), total cholesterol, cardiac Troponin T (TnT),
N-terminal fragment of pro-brain natriuretic peptide (NT-
proBNP) and CRP – which we consider the most relevant CV
biomarkers – between Dutch-Caucasian and Chinese DM2
patients presenting with acute coronary syndrome (ACS). In
particular, we aimed to reveal inter-ethnic differences in the
temporal evolution of these CV biomarkers during 1 year fol-
lowing the index ACS event.
Clinical significance
 Most cardiovascular biomarkers have been merely vali-
dated in Caucasians.
 Chinese populations are underreported in cardiovascular
biomarker research.
 LDL and total cholesterol are higher in Caucasians than in
Chinese.
 Troponin T and CRP are systematically higher in
Caucasians than in Chinese.
 Biomarkers studied in Caucasians may not be directly
extrapolated to Chinese.
Methods
Study design and patients
Figure 1 describes a patient flow diagram to illustrate the
flow of participants through the study. We selected 48
Chinese ACS patients with established DM2 from the ‘Peking
and Rotterdam on Mission to Reduce Coronary Artery
Disease’ (PRoMISS) study. PRoMISS is a prospective, observa-
tional study, conducted in 12 hospitals in the larger area of
Beijing (China), and enrolled patients during 2013–2014
admitted for an ACS and with a clinical diagnosis of DM2
prior to this index event. The definition of ACS covered
unstable angina pectoris (UAP), non-ST elevation myocardial
infarction (NSTEMI) and ST-elevation myocardial infarction
(STEMI). Blood samples (non-fasting) were taken from
Figure 1. Study flow chart. A patient flow diagram according to the international STARD guidelines to report flow of participants through the study.
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PRoMISS patients at the day of hospital admission, at the
day of hospital discharge, followed by monthly blood sample
collection until 1 year follow-up. Altogether a median of 9
repeated samples per patient were available in the Chinese
cohort.
Subsequently, we selected 48 DM2-ACS patients with
Caucasian ethnicity from the Dutch prospective, observa-
tional ‘BIOMarker study to identify the Acute risk of a
Coronary Syndrome’ (BIOMArCS) (Oemrawsingh et al. 2016).
BIOMArCS enrolled 844 ACS patients with and without
diabetes mellitus in 18 participating hospitals in The
Netherlands during 2008–2015. A subgroup of 23% (n¼ 196)
in this cohort was diagnosed with DM2. Patients underwent
blood sampling at admission, at the day of hospital dis-
charge and subsequently every fortnight during the first
6months after discharge, followed by monthly blood sample
collection until 1 year. A median of 16 repeated samples per
patient was available in BIOMArCS. Chinese-PRoMISS and
Caucasian-BIOMArCS patients were 1:1 matched on age
(±5 year range), sex, admission diagnosis, history of CAD, and
risk factor profile, including diabetes mellitus, hypercholester-
olaemia, hypertension, peripheral vascular disease and smok-
ing. At the time of matching, from the completed BIOMArCS
study 48 diabetic patients could be optimally paired accord-
ing to the matching criteria with 48 patients from the
ongoing PRoMISS study. None of the patients experienced a
recurrent ACS event throughout follow-up.
The PRoMISS and BIOMArCS studies were approved by
the medical ethics committees of the participating hospitals.
All participating patients from both studies provided written
informed consent. Information on baseline characteristics
and medication use was directly derived from patients’ med-
ical records and prospectively entered into a dedicated
database.
Biomarker analysis
In PRoMISS and BIOMArCS, after preparation, aliquots were
frozen at 80 degrees Celsius within two hours after with-
drawal. Blood samples were initially handled and securely
stored on-site, and then transported to the central laboratory
of the Peking University Third Hospital, Beijing, China
(PRoMISS) or the Erasmus MC, Rotterdam, the Netherlands
(BIOMArCS) for long-term storage. After completion of data
collection, blood samples were analysed batch-wise on the
Roche CobasVR 8000 analysis platform (e601 immunoassay
analyzer), using the fifth generation high sensitivity assay,
with the following reagents (Roche Diagnostics Mat.-No./
Genisys-No): HDL: 04399803190; LDL: 03038866322; total
cholesterol: 03039773190; TnT: 05092728190; NT-proBNP:
05390109190; CRP: 04628918190. PRoMISS and BIOMArCS
samples were analysed in two different central laboratories
(in China and the Netherlands), but the reagents, including
calibration and control materials, had the same production
lot number, and analysis protocols were identical had the
same production lot number and analysis protocols were
identical.
Statistical analysis
Categorical data are presented as numbers and percentages.
Continuous variables are presented as mean± standard devi-
ation (SD) in case of a normal distribution, or as median and
interquartile range (IQR) in case of a skewed distribution.
Normality of the distributions of continuous variables was
examined by visual inspection of the histogram and by nor-
mal Q–Q plots. The measured biomarkers showed a skewed
distribution and were therefore log2-transformed for analysis.
Missing values on baseline characteristics and medication
use were minimal (7% missing information on gender and
3% missings on type of medication used) and addressed by
complete case analysis. There were no missing values on bio-
marker levels.
Differences in baseline clinical characteristics between the
Chinese-PRoMISS and Caucasian-BIOMArCS patients were
evaluated by the paired samples t-test (for continuous varia-
bles), McNemar test (for categorical variables) or Marginal
Homogeneity (for categorical variables with more than two
categories) to account for the 1:1 matching.
Linear mixed effect (LME) models were applied with
nested random effects (to account for the paired data). A
grouping variable (PRoMISS or BIOMArCS) and time were
entered as fixed effects, and paired individuals were entered
as random effects, to determine mean biomarker levels in
both cohorts. Interaction terms (grouping variable x time)
were added (as fixed effects) to determine differences in bio-
marker evolution over time between the PRoMISS-Chinese
and BIOMArCS-Caucasian patients. LME analyses were con-
ducted with biomarker values on the log2 scale, but the
main results are presented on the linear scale for ease of
interpretation.
A substantial difference in medication use was observed
between the PRoMISS-Chinese and BIOMArCS-Caucasian
patients, which could have influenced biomarker levels.
Therefore, adjusted LME models were constructed, including
medication use (aspirin, statins, beta-blockers, ACE-inhibitors
or angiotensin-II receptor blockers, nitrates and anti-
diabetics) as potential confounding factors. Thereby a certain
amount of potential bias was addressed.
Data analyses were performed with SPSS version 21 and
RStudio software version 1.0.136. All statistical tests were
two-tailed and p-values <0.050 were considered statistically
significant.
Results
Patient characteristics
Baseline clinical characteristics of the two successfully
matched patient study cohorts are presented in Table 1. The
BIOMArCS-Caucasian and PRoMISS-Chinese patients had a
mean age of 60.2 ± 8.0 years and 60.0 ± 8.1, respectively. Most
patients were men (BIOMArCS 87.5%, PRoMISS 85.4%), pre-
senting with a STEMI (64.4% in both cohorts). As expected
after matching, baseline clinical characteristics and cardiovas-
cular risk factors were similarly distributed in the two study
cohorts. Overall, commonly prescribed cardiovascular drugs
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after an ACS were more frequently used in the BIOMArCS-
Caucasian patients than in the PRoMISS-Chinese patients, in
particular beta-blockers (BIOMArCS 91.7%, PRoMISS 68.8%,
p¼ 0.007), nitrates (BIOMArCS 25.0%, PRoMISS 0%, p< 0.001)
and anti-diabetics (BIOMArCS 89.6%, PRoMISS 68.8%
p¼ 0.021).
Biomarker trajectories
BIOMArCS-Caucasian patients had statistically significant
higher mean longitudinal levels for most lipid biomarkers
than their PRoMISS-Chinese counterparts. Especially, clinically
relevant higher mean LDL (2.16 vs. 1.47mmol/L; p-value
<0.001) and total cholesterol (4.08 vs. 3.11mmol/L; p-value
<0.001) levels were found (Figure 2, Table 2). These differen-
ces persisted and remained significant in a subanalysis of sta-
tin users only (results not shown). The estimated mean lipid
biomarker levels did not change during the study period in
BIOMArCS-Caucasian patients (Figure 2, Supplementary Table
1). In PRoMISS-Chinese patients, however, these biomarkers
had a slight, but statistically significant, tendency to increase
over time. Since the monthly increase was only 0.5% (choles-
terol) to 4.3% (HDL) of the longitudinal mean level, the dif-
ferences between BIOMArCS and PRoMISS remained fairly
constant during the >30 days post ACS study period.
With respect to the established non-lipid cardiovascular
biomarkers that we studied: BIOMArCS-Caucasians had
higher mean longitudinal levels of TnT (11.0 vs. 7.76 ng/L; p-
value 0.010) and CRP (2.07 vs. 0.78mg/L; p-value <0.001)
than PRoMISS-Chinese patients (Figure 3, Table 2). NT-
proBNP levels were similar. In both cohorts, TnT, NT-proBNP
and CRP slightly decreased over time (Figure 3,
Supplementary Table 1), with a somewhat steeper decline in
NT-proBNP in PRoMISS. Again, however, the monthly
changes were far smaller than the longitudinal mean levels,
so that the BIOMArCS-PRoMISS differences in mean levels
were factually time-independent.
Discussion
This study investigated temporal cardiovascular biomarker
profile differences between Caucasian and Chinese DM2
patients by high-frequency blood sampling during 1 year
after their ACS index event. Overall, we found persistently
higher levels of LDL, total cholesterol, TnT and CRP in
Caucasian patients as compared to Chinese patients. We did
not observe significant differences in HDL and NT-proBNP
values between the two cohorts.
In general, studies investigating inter-ethnic cardiovascular
biomarker differences between Caucasian and Chinese
patients in a CAD population have barely been performed.
So far, only one systematic review has reported differences
in ten conventional cardiovascular biomarkers between
diverse ethnic Asian groups and Caucasians in the general
population (Gijsberts et al. 2015). It is important to note that
only 5 out of the 33 studied cohorts were from Chinese ori-
gin, of which only 1 resided in the country of origin. The
vast majority of biomarker levels was described in South
Table 1. Baseline clinical characteristics of the (matched) study patients.
BIOMArCS-Caucasian (n¼ 48) PRoMISS-Chinese (n¼ 48) p Value
Patient characteristics
Age, years 60.2 ± 8.0 60.0 ± 8.1 0.89
Male gender, n (%) 42 (87.5) 41 (85.4) 0.25
Admission diagnosis, n (%) 1.00
STEMI 31 (64.6) 31 (64.6)
NSTEMI 10 (20.8) 10 (20.8)
UAP 7 (14.6) 7 (14.6)
Cardiovascular risk factors, n (%)
Smoking 0.56
Current 20 (41.7) 16 (33.3)
Former 11 (22.9) 14 (29.2)
Never 17 (35.4) 18 (37.5)
Diabetes Mellitus 48 (100.0) 48 (100.0) 1.00
Hypertension 31 (64.6) 33 (68.8) 0.80
Hypercholesterolaemia 27 (56.2) 25 (52.1) 0.79
Medical history, n (%)
Previous myocardial infarction 10 (20.8) 7 (14.6) 0.55
Previous PCI 10 (20.8) 7 (14.6) 0.51
Previous CABG 5 (10.4) 0 (0.0) 0.06
Previous stroke 2 (4.2) 2 (4.2) 1.00
History of peripheral vascular disease 2 (4.2) 0 (0.0) 0.50
Medication use at first blood sample moment >30 days after admission, n (%)
Aspirin 46 (95.8) 42 (87.5) 0.29
Statin 45 (93.8) 37 (77.1) 0.06
Beta-blocker 44 (91.7) 33 (68.8) 0.007
ACE-inhibitor or ARB 38 (79.2) 29 (60.4) 0.06
Nitrates 12 (25.0) 0 (0.0) <0.001
Anti-diabetics 43 (89.6) 33 (68.8) 0.021
Values are expressed as mean ± standard deviation or proportion, n (%). p-values were obtained by paired samples t-test (for the continuous variable), McNemar
test (for categorical variables) or Marginal Homogeneity (for categorical variables with more than two categories), whichever was appropriate.
ARB: angiotensin II receptor blocker; CABG: coronary artery bypass graft surgery; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment
elevation myocardial infarction; UAP: unstable angina pectoris.
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Asians, who are known to carry a more unfavourable cardio-
vascular risk and biomarker profile. Thus, sufficient evidence
on inter-ethnic biomarker differences with data from Chinese
CAD individuals is currently lacking. This underscores the
need for ethnicity-driven biomarker research with a specific
focus on Chinese individuals with CAD. Furthermore, the
observed blood biomarker differences are based on only one
blood sample, which reflects a snapshot and not a state dur-
ing a longer period.
The importance of investigating this matter is endorsed
by evidence that some biomarkers (e.g. CRP, IL-6, fibrino-
gen) were not able to predict incident CAD events risk
Figure 2. Serial measurements and temporal evolvement of lipid biomarkers in the BIOMArCS-Caucasian and PRoMISS-Chinese patients. The graphs show evolve-
ment of HDL, LDL and total cholesterol >30 days since the index ACS event until 1-year in Caucasian (left) and Chinese (right) patients, who have not experienced
a recurrent event during follow-up. The points represent measurements in individual patients. The bold line in each graph represents the average value, using lin-
ear mixed models with nested random effects. HDL: high-density lipoprotein; LDL: low-density lipoprotein.
Table 2. Mean biomarker levels in the study patients 30 days to 1 year after the index ACS admission.
BIOMArCS-Caucasian (n¼ 48) PRoMISS-Chinese (n¼ 48) Mean difference (95% CI) p Value
HDL, mmol/L 0.97 (0.81–1.15) 0.94 (0.81–1.10) 0.03 (0.06–0.13) 0.491
LDL, mmol/L 2.16 (1.60–2.94) 1.47 (1.11–1.89) 0.69 (0.40–1.04) <0.001
Cholesterol, mmol/L 4.08 (3.34–4.92) 3.11 (2.66–3.64) 0.97 (0.62–1.37) <0.001
Troponin T, ng/L 11.04 (6.40–18.10) 7.76 (5.07–12.27) 3.28 (0.71–6.62) 0.010
NT-proBNP, pmol/L 13.47 (5.85–31.58) 15.97 (7.73–31.79) 2.50 (7.42–5.28) 0.457
CRP, mg/L 2.07 (0.88–4.80) 0.78 (0.38–1.68) 1.28 (0.69–2.12) <0.001
Data represent mean (95% confidence interval) biomarker values that were derived from nested linear mixed effects models, with adjustment for
the use of cardiovascular medication, including aspirin, statins, beta-blockers, ACE-inhibitors or angiotension-II receptor blockers, nitrates and
anti-diabetics.
CRP: C-reactive Protein; HDL: High-density Lipoprotein; LDL: Low-density Lipoprotein; NT-proBNP: N-terminal pro B-type Natriuretic Peptide.
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among asymptomatic Chinese people in contrast to positive
associations found in Caucasians (Veeranna et al. 2013).
Therefore, it seems inevitable to create ethnic-specific cut-
off points in order to detect high-risk individuals for risk
stratification. Although it has been demonstrated that these
biomarkers retain their predictive value in Chinese cohorts
despite their lower values, clear cut-off points are not
known and should be further investigated. Also it is a mat-
ter of debate whether patients with lower values (e.g. LDL,
CRP) would still benefit from treatment with anti-inflamma-
tory agents or statins. For example, it seems that Asian
patients are likely to benefit from lowering LDL by statins
despite their lower values (Sakamoto and Ogawa 2010).
However, the threshold for treatment initiation and targets
for treatment follow-up are possibly lower than for
Caucasians. These thresholds and targets need to be deter-
mined in future studies as well.
With regard to our findings in the lipid profile, marked
differences were found between Chinese and Caucasians
during follow-up. Overall, except for HDL, average mean lev-
els of LDL and total cholesterol were significantly lower in
Chinese than Caucasian patients. Differences in lipid profile
among ethnic groups have been described by previous stud-
ies before and are in accordance with our results (Goff et al.
2006, Frank et al. 2014). Especially Chinese have been
pointed out to possess a favourable lipid profile (Anand
et al. 2000). An analysis from the INTERHEART study obtained
one non-fasting blood sample from 5731 myocardial infarc-
tion patients and 6469 non-cardiac patients to investigate
lipid abnormalities among Asian subgroups (Karthikeyan
et al. 2009). In particular, among the various Asian sub-
groups, Chinese patients tended to have the lowest LDL lev-
els, but not HDL.
Further, our study showed that on the long run TnT and
NT-proBNP levels varied in a similar range in the two
cohorts and were not different from each other. This is in
contrast to recent findings from the Multi-Ethnic Study of
Atherosclerosis, where it has been demonstrated that
Figure 3. Serial measurements and temporal evolvement of acute-phase biomarkers in the BIOMArCS-Caucasian and PRoMISS-Chinese patients. The graphs show
evolvement of Troponin T, NT-proBNP and CRP >30 days since the index ACS event until 1-year in Caucasian (left) and Chinese (right) patients, who have not expe-
rienced a recurrent event during follow-up. The points represent measurements in individual patients. The bold line in each graph represents the average value,
using linear mixed models with nested random effects. CRP: C-reactive Protein; NT-proBNP: N-Terminal fragment of Pro-Brain Natriuretic Peptide.
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Chinese individuals possessed the lowest NT-proBNP levels
based upon genetics (Gupta et al. 2017). However, this study
included asymptomatic individuals without prevalent cardio-
vascular disease and only a small proportion consisted of
Chinese individuals (13%), in whom NT-proBNP levels were
measured once at baseline. Further, ethnicity was self-
reported, which may have resulted in misclassification.
Altogether, the discrepancy with our findings could have
been due to a different study population and design.
Lastly, remarkable differences regarding CRP in our study
were present. The fact that Chinese patients had sustainably
lower levels of CRP than Caucasians in our study is in accord-
ance with existing evidence on CRP in various ethnic groups
(Lakoski et al. 2006, Saito et al. 2007, Kelley-Hedgepeth et al.
2008, Saito et al. 2014, Sung et al. 2014). The underlying
pathophysiological mechanism for lower CRP levels in
Chinese individuals is unknown, but is speculated to be
based upon differences in body mass index and genetics
(Kelley-Hedgepeth et al. 2008, Saito et al. 2014).
Nevertheless, despite lower CRP levels, they still independ-
ently predict cardiovascular as well as all-cause mortality in
Asian populations (Saito et al. 2014, Sung et al. 2014).
Our study has several limitations. Firstly, due to border
law regulations, blood samples could not be shipped from
China and therefore needed to be analysed in two separate
laboratories. Thus, some amount of analytical variation differ-
ences was unavoidable and might have influenced our
results. Secondly, with regard to our findings in the lipid pro-
file, we accounted for differences in prevalence of statin use
between BIOMArCS-Caucasians and PRoMISS-Chinese in the
analysis, but we had no data on the (dynamic changes in)
statin dosage. Nevertheless, from empiric data it is most
likely that Caucasian patients were prescribed more often
high-intensity statin therapy than Chinese patients, which
emphasizes the importance of the observed differences in
lipid values even more. Furthermore, we do not have specific
information on the ‘clinical phenotype’ of our studied
patients, such as left ventricular ejection fraction, infarct size
and severity of vessel disease, which might be confounders
of the observed biomarker differences between the cohorts.
However, by matching on clinical characteristics and admis-
sion diagnosis, we tried to limit this type of confounding.
Another important limitation is the lack of information on
genetic and environmental factors, since the observed differ-
ences could partly be due to divergent genetic makeup and
different lifestyle (e.g. dietary factors, physical activity). Lastly,
blood samples were not fasting samples. Nevertheless, HDL,
LDL and total cholesterol are recognized as being relatively
unaffected by the non-fasting state. Also, a non-fasting state
reflects a state in which patients often present in the hos-
pital and thus mimics clinical practice.
Conclusion
Frequent blood sampling during 1 year post ACS enabled us
to reveal that most conventional biomarkers were remarkably
lower in diabetic CAD participants from Chinese than
Caucasian origin. This could give more insight into blood
biomarker related differences among ethnic groups and
might serve as a reference pilot study for larger future CAD
studies. Our findings underscore the fact that it may not be
convenient to apply findings from most Western cohorts to
Chinese individuals. In order to provide accurate risk stratifi-
cation for prediction and treatment benefit, further research
should focus on defining clear cut-off values in primary and
secondary prevention for each specific ethnic group.
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